Overview
- Pfizer reported third-quarter revenue of $16.58 billion and adjusted EPS of $0.87, results the company said topped analyst estimates after its Tuesday earnings release.
- The company raised full-year 2026 guidance to $62 billion–$64 billion and lifted adjusted EPS guidance to $2.95–3.05 per share based on year-to-date performance.
- Sales of non-COVID medicines led the upside, with Eliquis reaching $2.52 billion (about 25% growth) and strong gains from Padcev and other recently launched or acquired products.
- COVID-19 product sales continued to decline sharply, with Paxlovid and Comirnaty reporting large year-over-year drops, and Pfizer plans roughly $9.7 billion in net cost savings through 2029 to offset those losses.
- Cecile Guegan, who served as interim CFO since August, was named permanent chief financial officer as Pfizer reorients capital and R&D plans toward its broader drug portfolio.